Suchergebnisse - "Bylicki, Olivier"

PubPharm (5)

1

Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2023

von Heymach, J. | Harpole, D. | Mitsudomi, T. | +125

CommentIn: N Engl J Med. 2024 Jan 18;390(3):287. - PMID 38231634

2

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2023

von Wakelee, H. | Liberman, M. | Kato, T. | +117

CommentIn: Transl Lung Cancer Res. 2023 Nov 30;12(11):2359-2365. - PMID 38090512

3

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2) : a multicentre, open-label, randomised, non-comparative, phase 2 trial

enthalten in: The Lancet. Oncology | 2019

von Scherpereel, A. | Mazieres, J. | Greillier, L. | +22

CommentIn: Lancet Oncol. 2019 Feb;20(2):172-174. - PMID 30660608

4

Stay and play eFAST or scoop and run eFAST? That is the question!

enthalten in: The American journal of emergency medicine | 2014

von Brun, P. | Bessereau, J. | Chenaitia, H. | +6

5

Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2013

von Bylicki, O. | Ferlay, C. | Chouaid, C. | +17

1
[1]